ARCHIVES

Efaproxyn Improved Survival Of Patients With Brain Mets

This article is from The Cancer Letter archive.

Vol. 27 No. 10 | October 29, 2004

Download PDF Visit The Full Archive

Related Articles

Phase III Trial Would Give Clearer Picture of C225 Role

March 8, 2002

FDA Caps Advisors’ Holdings To $50,000 In Firms Affected By Committee Meetings.

August 8, 2008

Study Identifies Risk Factors To Predict Contralateral Cancer

February 27, 2009

Reponses To Ford’s Request For Scientific Rational Of Cigarette Regulation Based On Epidemiologic Studies

November 8, 1974

Guest Editorial: Guideline Promises to End Twenty-Year War Over Mass Screening for Prostate Cancer

May 24, 2013

In Brief: HEW Opposes Research Contract Peer review; Congressman Blass Inadequate Grant Funds

May 10, 1974